VR Adviser’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

VR Adviser’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,016,873	Closed	-$94M	–	37
2021 Q1	$94M	Hold	4,016,873	–	–	10.19%	2
2020 Q4	$116M	Hold	4,016,873	–	–	17.01%	1
2020 Q3	$81.4M	Hold	4,016,873	–	–	15.92%	2
2020 Q2	$121M	Hold	4,016,873	–	–	28.9%	1
2020 Q1	$126M	Buy	+4,016,873	New	+$140M	34.2%	1

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser's CNST Position: Q2 2021 in Review

VR Adviser sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 4,016,873 shares — an estimated $94M sold.

VR Adviser first reported a position in CNST in Q1 2020 and held it in 5 quarters. The position peaked at $126M in Q1 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

VR Adviser reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
VR Adviser sold 4,016,873 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $94M.
VR Adviser first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2020 and held it in 5 quarters.
VR Adviser's Constellation Pharmaceuticals, Inc. position peaked at $126M in Q1 2020.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on VR Adviser's 13F filing for Q2 2021, filed 13 Aug 2021.